Singular Research reissued their buy-venture rating on shares of FSD Pharma (CVE:HUG – Free Report) in a report published on Tuesday morning, Zacks.com reports. Singular Research also issued estimates for FSD Pharma’s Q1 2024 earnings at ($0.07) EPS, Q2 2024 earnings at ($0.08) EPS, Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.16) EPS.
FSD Pharma Stock Performance
FSD Pharma (CVE:HUG – Get Free Report) last issued its earnings results on Thursday, March 28th. The company reported C($0.05) earnings per share (EPS) for the quarter.
See Also
- Five stocks we like better than FSD Pharma
- How is Compound Interest Calculated?
- Roblox: The Bottom Just Fell Out of the Metaverse
- Why Are Stock Sectors Important to Successful Investing?
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.